{"id":"CHEMBL101253","canonicalSmiles":"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1","inchiKey":"YCOYDOIWSSHVCK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VATALANIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY-86-5127","CGP-79787","K-222584","NVP-PTK787","PTK-787","PTK787","Ptk-787","Vatalanib","Vatalanib succinate","ZK-222584","ZK222584"],"crossReferences":{"PubChem":["103905548","104171421","144206361","170466113","50100112"],"Wikipedia":["Vatalanib"],"drugbank":["DB04879"],"chEBI":["90620"]},"childChemblIds":["CHEMBL75232","CHEMBL2142861"],"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000102755","ENSG00000037280","ENSG00000113721","ENSG00000157404","ENSG00000182578"],"count":7},"linkedDiseases":{"rows":["EFO_0003869","EFO_0001365","EFO_1001901","EFO_0000756","MONDO_0007254","EFO_1000657","MONDO_0002087","EFO_0002430","Orphanet_892","MONDO_0002158","EFO_0000339","EFO_0000588","MONDO_0002974","EFO_0000389","EFO_0004288","EFO_1000158","EFO_0002618","EFO_0000616","MONDO_0008170","EFO_0000403","EFO_0000222","MONDO_0008315","EFO_0003060","EFO_0000311","EFO_0009708","MONDO_0011962","MONDO_0002367","EFO_0001378","EFO_0000691","EFO_0000519"],"count":30},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications."}
{"id":"CHEMBL104937","canonicalSmiles":"N=C(N)c1ccc2cc(C(=O)Nc3ccccc3)ccc2c1","inchiKey":"AECPTICWHONWNW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL104937","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01977"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1093743","canonicalSmiles":"CCCCC/C=C\\C=C\\CCCCCCCCC(=O)O","inchiKey":"GKJZMAHZJGSBKD-NMMTYZSQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1093743","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04746"],"chEBI":["44526"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1101","canonicalSmiles":"OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2","inchiKey":"YSXKPIUOCJLQIE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIPERIDEN","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Akineton"],"synonyms":["Akineton","Akineton-","Biperiden","Biperidenum","KL 373","NSC-759145"],"crossReferences":{"PubChem":["124894170","174006780","90341640"],"Wikipedia":["Biperiden"],"drugbank":["DB00810"],"chEBI":["3112"]},"childChemblIds":["CHEMBL1201035","CHEMBL1201067"],"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0002610","MONDO_0002050","HP_0000726","MONDO_0005180","MONDO_0043510","EFO_0005230"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for parkinson disease and has 6 investigational indications."}
{"id":"CHEMBL113051","canonicalSmiles":"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2/C=N/OC(C)(C)C","inchiKey":"UIVFUQKYVFCEKJ-OPTOVBNMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GIMATECAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gimatecan"],"crossReferences":{"PubChem":["170465615"],"drugbank":["DB06721"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1173532","canonicalSmiles":"COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2","inchiKey":"ICXJGCSEMJXNQF-ZIAGYGMSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane (enantiomeric mix)"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1200380","canonicalSmiles":"Nc1nc([O-])c2ncn(COCCO)c2n1.[Na+]","inchiKey":"RMLUKZWYIKEASN-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"ACYCLOVIR SODIUM","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL184","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Acyclovir","Acyclovir sodium","Zovirax"],"synonyms":["Aciclovir sodium","Acyclovir","Acyclovir sodium","Acyclovir sodium salt","BW 248U","BW 248U SODIUM","BW-248U SODIUM","BW-248U-SODIUM","Sodium acyclovir"],"crossReferences":{"DailyMed":["acyclovir%20sodium"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for genital herpes and has 14 investigational indications."}
{"id":"CHEMBL1200391","canonicalSmiles":"NC(CO)(CO)CO","inchiKey":"LENZDBCJOHFCAS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TROMETHAMINE","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tham"],"synonyms":["NSC-6365","Tris(hydroxymethyl)aminomethane","Tris-base","Trizma","Trometamol","Tromethamine"],"crossReferences":{"DailyMed":["tromethamine"],"PubChem":["144208844","144213484","170464686","29215348","29215349"],"Wikipedia":["Tris"],"drugbank":["DB03754"],"chEBI":["9754"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for acidosis and has 7 investigational indications."}
{"id":"CHEMBL1200458","canonicalSmiles":"O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+]","inchiKey":"QEEAPRPFLLJWCF-UHFFFAOYSA-K","drugType":"Small molecule","blackBoxWarning":false,"name":"POTASSIUM CITRATE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Potassium Citrate","Urocit-K"],"synonyms":["E-332(II)","E332","INS NO.332(II)","INS-332(II)","NSC-760107","Potassium citrate","Potassium citrate monohydrate"],"crossReferences":{"DailyMed":["potassium%20citrate"],"DrugCentral":["4519"],"Wikipedia":["Potassium_citrate"],"drugbank":["DB09125"],"chEBI":["64733"]},"childChemblIds":["CHEMBL3989822"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for renal tubular acidosis and has 3 investigational indications."}
{"id":"CHEMBL1200467","canonicalSmiles":"O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1","inchiKey":"ASDOKGIIKXGMNB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROXYZINE PAMOATE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL896","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["\"hy-pam \"\"25\"\"\"","Hy-Pam \"25\"","Hy-pam","Hydroxyzine pamoate","Vistaril"],"synonyms":["Hydroxyzine embonate","Hydroxyzine pamoate","NSC-757063"],"crossReferences":{"DailyMed":["hydroxyzine%20pamoate"],"PubChem":["124886739","26748082","855631"],"chEBI":["31680"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0005531","HP_0000989","EFO_0006788","EFO_0000701","EFO_0004257"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 5 approved indications."}
{"id":"CHEMBL1200475","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O","inchiKey":"VNTHYLVDGVBPOU-QQYBVWGSSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DAUNORUBICIN CITRATE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL178","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Daunoxome"],"synonyms":["Daunorubicin citrate","Daunorubicin citrate liposome","Daunorubicin liposomal"],"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","MONDO_0007254","EFO_0000691"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200560","canonicalSmiles":"CC(=O)O.N=C(N)N/N=C/c1c(Cl)cccc1Cl","inchiKey":"MCSPBPXATWBACD-GAYQJXMFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUANABENZ ACETATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL420","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Guanabenz acetate","Wytensin"],"synonyms":["Guanabenz acetate","Guanabenz monoacetate","NSC-757044","WY-8678","WY-8678 ACETATE"],"crossReferences":{"PubChem":["50106405"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201066","canonicalSmiles":"COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl","inchiKey":"QYRYFNHXARDNFZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VENLAFAXINE HYDROCHLORIDE","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL637","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Effexor","Effexor xr","Venlafaxine hydrochloride"],"synonyms":["NSC-745751","Venlafaxine (as hydrochloride)","Venlafaxine hcl","Venlafaxine hydrochloride","WY-45,030","WY-45030"],"crossReferences":{"DailyMed":["venlafaxine%20hydrochloride"],"PubChem":["144212825","49681556"],"chEBI":["9944"]},"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["EFO_0006862","MONDO_0005090","EFO_0002610","EFO_0004262","EFO_0005687","MONDO_0002009","HP_0000726","EFO_1001919","MONDO_0007254","EFO_1002014","EFO_1001917","HP_0031217","MONDO_0005277","EFO_0000289","MONDO_0002050","MONDO_0005180","EFO_0000673","EFO_0003761","EFO_0009854","EFO_0004242","EFO_0005230","EFO_0005762","EFO_0006788","EFO_0001358","MONDO_0008315","EFO_1001892","HP_0030833","MONDO_0004975","MONDO_0043510","EFO_0003918"],"count":30},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 19 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1222251","canonicalSmiles":"O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O","inchiKey":"CDAISMWEOUEBRE-GPIVLXJGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INOSITOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cyclohexanehexol","I-inositol","Inositol","Inositol, myo","Inositol, myo-","Meso-inositol","Myo-inositol","NSC-25142","NSC-404118","NSC-55551","NSC-8101"],"crossReferences":{"PubChem":["144205195","144212352","170465541","29215342","56324719","73813"],"Wikipedia":["Inositol"],"drugbank":["DB13178"],"chEBI":["17268"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL1230365","canonicalSmiles":"COc1cc(C(C)(C)C#Cc2c(C)nc(N)nc2N)cc(OC)c1OC","inchiKey":"FJNFXXGWYVMQNA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230365","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07153"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1230617","canonicalSmiles":"Nc1ncnc2c1nc(Br)n2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"DNPIJKNXFSPNNY-UUOKFMHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"8-Bromo-Adenosine Mono Phosphate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["8-Bromo-Adenosine Mono Phosphate"],"crossReferences":{"drugbank":["DB03349"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231193","canonicalSmiles":"NS(=O)(=O)c1cc2c(cc1Cl)N[C@@H](C(Cl)Cl)NS2(=O)=O","inchiKey":"LMJSLTNSBFUCMU-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231193","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11112292"],"drugbank":["DB08645"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231644","canonicalSmiles":"C[As](C)(=O)O","inchiKey":"OGGXGZAMXPVRFZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CACODYLIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144211084","26747794","26753706","29215173","405276","93576721"],"drugbank":["DB02994"],"chEBI":["48765"]},"childChemblIds":["CHEMBL2079844","CHEMBL1877702"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233024","canonicalSmiles":"Fc1ccc(-c2n[nH]cc2-c2ccncc2)cc1","inchiKey":"BILJSHVAAVZERY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1233024","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07829"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236235","canonicalSmiles":"Cc1ncc(C[n+]2csc(CCOP(=O)([O-])OP(=O)(O)O)c2C)c(N)n1","inchiKey":"AYEKOFBPNLCAJY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THIAMIN DIPHOSPHATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Thiamin Diphosphate"],"crossReferences":{"drugbank":["DB01987"],"chEBI":["45931"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236302","canonicalSmiles":"N[C@@H](Cc1cccs1)C(=O)O","inchiKey":"WTOFYLAWDLQMBZ-LURJTMIESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1236302","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03673"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236595","canonicalSmiles":"COC1=C(OC)C(=O)C(C/C=C(\\C)CCC=C(C)C)=C(C)C1=O","inchiKey":"SQQWBSBBCSFQGC-JLHYYAGUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Coenzyme Q2","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08690"],"chEBI":["46372"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1237","canonicalSmiles":"NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O","inchiKey":"RLAWWYSOJDYHDC-BZSNNMDCSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LISINOPRIL","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Prinivil","Zestril"],"synonyms":["Lisinopril","MK-521","NSC-751176","NSC-758151"],"crossReferences":{"DailyMed":["lisinopril"],"PubChem":["50085996"],"Wikipedia":["Lisinopril"],"drugbank":["DB00722"],"chEBI":["43755"]},"childChemblIds":["CHEMBL419213","CHEMBL1729579"],"linkedTargets":{"rows":["ENSG00000159640"],"count":1},"linkedDiseases":{"rows":["EFO_0000401","EFO_1001249","MONDO_0007254","EFO_0000373","MONDO_0002462","EFO_1002034","EFO_1000948","EFO_0003914","Orphanet_416","EFO_0002690","EFO_1001375","EFO_0003144","EFO_0000279","EFO_0000182","EFO_0000712","EFO_0000400","EFO_0008620","HP_0003124","EFO_0001645","EFO_0000319","EFO_0004236","EFO_0004194","EFO_0000537","EFO_0003896","MONDO_0001134","Orphanet_79292","EFO_0000764","EFO_0000574","EFO_0000612","MONDO_0005148","HP_0012594","EFO_0004264"],"count":32},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL12610","canonicalSmiles":"CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12","inchiKey":"CNBGNNVCVSKAQZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZYDAMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Apo-benzydamine","Benzindamine","Benzydamine"],"crossReferences":{"PubChem":["11112291","160657813"],"Wikipedia":["Benzydamine"],"drugbank":["DB09084"]},"childChemblIds":["CHEMBL1528134"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["HP_0002829","HP_0003326","EFO_1001216","EFO_0009688","MONDO_0002258","EFO_0003843","EFO_0005755","EFO_0005757","EFO_1001904"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL129857","canonicalSmiles":"COc1cccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c12","inchiKey":"GZGLPBNOIFLLRE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AS-602868","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["As-602868","SPC-839"],"crossReferences":{"PubChem":["137275813","26755375"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1382","canonicalSmiles":"Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1","inchiKey":"OOGJQPCLVADCPB-HXUWFJFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOLTERODINE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Blerone xl","Detrusitol","Detrusitol xl","Efflosomyl xl","Inconex xl","Mariosea xl","Neditol xl","Preblacon xl","Santizor xl"],"synonyms":["KABI 2234","KABI-2234","Tolterodine"],"crossReferences":{"DailyMed":["tolterodine%20tartrate"],"PubChem":["144205290","170465337","29215497","49666284"],"Wikipedia":["Tolterodine"],"drugbank":["DB01036"],"chEBI":["9622"]},"childChemblIds":["CHEMBL1200871","CHEMBL1722209"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["EFO_0005762","HP_0012532","HP_0006000","EFO_0004253","EFO_0006865","HP_0000020","EFO_1000781","EFO_0000284","HP_0003419","EFO_0003843","EFO_0004710","HP_0000103"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 6 investigational indications."}
{"id":"CHEMBL141305","canonicalSmiles":"CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1","inchiKey":"GVOUFPWUYJWQSK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCLOFENIL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"],"classes":["Hepatotoxicity"],"year":1987},"tradeNames":["Neoclym","Rehibin"],"synonyms":["Cyclofenil","F 6066","F-6066","ICI 48213","ICI-48213","NSC-86464","Sexovid"],"crossReferences":{"PubChem":["144205812","170465970","29217524"],"drugbank":["DB13472"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in France  in 1987 due to Hepatotoxicity."}
{"id":"CHEMBL1446","canonicalSmiles":"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.O=S(=O)(O)O","inchiKey":"OOYGSFOGFJDDHP-KMCOLRRFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KANAMYCIN SULFATE","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1384","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kanamycin sulfate","Kantrex","Klebcil"],"synonyms":["Kanamycin a sulfate","Kanamycin a sulphate","Kanamycin monosulfate","Kanamycin monosulphate","Kanamycin sulfate","NSC-757068"],"crossReferences":{"PubChem":["121269829","144204163","144210015"],"chEBI":["6109"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 2 investigational indications."}
{"id":"CHEMBL1478530","canonicalSmiles":"CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12","inchiKey":"FKNXQNWAXFXVNW-BLLLJJGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1478530","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11113915","144204492","170465820","26752069"],"drugbank":["DB01366"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1527608","canonicalSmiles":"Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O","inchiKey":"HWXIGFIVGWUZAO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOXOFYLLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Maxivent"],"synonyms":["ABC 12/3","Ansimar","Dioxyfilline","Doxofylline","Doxophylline","NSC-759645","Synasma","Ventax"],"crossReferences":{"PubChem":["144205130","170466312","29215238","49645880"],"drugbank":["DB09273"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1529","canonicalSmiles":"Cl.OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1","inchiKey":"AVZIYZHXZAYGJS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPHENIDOL HYDROCHLORIDE","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL936","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vontrol"],"synonyms":["Cephadol","Diphenidol hcl","Diphenidol hydrochloride","NSC-23012","SK&F 478-A","SK-478-A"],"crossReferences":{"PubChem":["11533019","85273789"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."}
{"id":"CHEMBL155572","canonicalSmiles":"NCc1ccccc1O","inchiKey":"KPRZOPQOBJRYSW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-Aminomethyl-Phenol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Aminomethyl-Phenol"],"crossReferences":{"drugbank":["DB14855"]},"childChemblIds":["CHEMBL3114402"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL15677","canonicalSmiles":"O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl","inchiKey":"IDKAXRLETRCXKS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENCLOFENAC","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Carcinogenicity"," Dermatological toxicity"],"year":1984},"tradeNames":[],"synonyms":["Fenclofenac","R 67408","R-67408","RX 67408","RX-67408"],"crossReferences":{"PubChem":["144206863"],"Wikipedia":["Fenclofenac"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978. It was withdrawn in United Kingdom  in 1984 due to Carcinogenicity and  Dermatological toxicity."}
{"id":"CHEMBL1614","canonicalSmiles":"C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@]4(C)[C@H]5C[C@@H](O)[C@]6(C)[C@@H](C7=CC(=O)OC7)CC[C@]6(O)[C@@H]5CC[C@@H]4C3)O[C@@H]2C)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](C)O1","inchiKey":"OBATZBGFDSVCJD-LALPQLPRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DESLANOSIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cedilanid-d"],"synonyms":["Deacetylanatoside c","Desacetyl-lanatoside c","Deslanoside"],"crossReferences":{"PubChem":["144205224","170465236"],"Wikipedia":["Deslanoside"],"drugbank":["DB01078"],"chEBI":["31468"]},"linkedTargets":{"rows":["ENSG00000163399","ENSG00000018625","ENSG00000105409","ENSG00000132681"],"count":4},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease."}
{"id":"CHEMBL1685","canonicalSmiles":"C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N","inchiKey":"VTMVHDZWSFQSQP-VBNZEHGJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEZOCINE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dalgan"],"synonyms":["Dezocine","Docozine","Dozocine","WY-16,225","WY-16225"],"crossReferences":{"Wikipedia":["Dezocine"],"drugbank":["DB01209"],"chEBI":["4474"]},"linkedTargets":{"rows":["ENSG00000082556","ENSG00000112038"],"count":2},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for pain."}
{"id":"CHEMBL16958","canonicalSmiles":"O=C1NCc2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21","inchiKey":"MEXUTNIFSHFQRG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"STAUROSPORINONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["K-252C"],"crossReferences":{"PubChem":["50112993"],"drugbank":["DB08036"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1742428","canonicalSmiles":"N#Cc1ccc(N2CCN(C(=O)COc3ccc4[nH]cc(CCN)c4c3)CC2)cc1","inchiKey":"SOHCKWZVTCTQBG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DONITRIPTAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Donitriptan","Donitriptan hydrochloride","F-11356"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL1742466","canonicalSmiles":"CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1","inchiKey":"WMDSZGFJQKSLLH-RBBKRZOGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LANDIOLOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AOP-200704","AOP200704","LDLL-600","LDLL600","Landiolol","ONO-1101"],"crossReferences":{"drugbank":["DB12212"]},"childChemblIds":["CHEMBL2362410"],"linkedTargets":{"rows":["ENSG00000043591"],"count":1},"linkedDiseases":{"rows":["EFO_0006834","EFO_0004269","EFO_0000275","EFO_0000319"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1743043","drugType":"Antibody","blackBoxWarning":true,"name":"MOXETUMOMAB PASUDOTOX","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lumoxiti"],"synonyms":["CAT-8015","HA-22","HA22","Moxetumomab pasudotox","Moxetumomab pasudotox-tdfk"],"crossReferences":{"DailyMed":["moxetumomab%20pasudotox-tdfk"]},"linkedTargets":{"rows":["ENSG00000167658","ENSG00000012124"],"count":2},"linkedDiseases":{"rows":["EFO_0000565","EFO_0000616","EFO_1000956","EFO_0000095","EFO_0000220","EFO_0000574","MONDO_0000870","EFO_0005952"],"count":8},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for neoplasm and hairy cell leukemia and has 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1743060","drugType":"Antibody","blackBoxWarning":false,"name":"RADRETUMAB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Radretumab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1743085","drugType":"Antibody","blackBoxWarning":false,"name":"URELUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-663513","Urelumab"],"linkedTargets":{"rows":["ENSG00000049249"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","EFO_0002618","EFO_0000616","EFO_0000096","EFO_0000756","EFO_1001465","EFO_0001378","EFO_0005952","EFO_0003060","EFO_0000311"],"count":10},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL1829335","canonicalSmiles":"C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1","inchiKey":"XUKROCVZGZNGSI-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IRDABISANT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CEP-26401","Cep 26401","Irdabisant"],"crossReferences":{"drugbank":["DB12900"]},"childChemblIds":["CHEMBL1813067"],"linkedTargets":{"rows":["ENSG00000101180"],"count":1},"linkedDiseases":{"rows":["HP_0100543"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1865134","canonicalSmiles":"CC(C)(C)c1ccc2c(S(=O)(=O)O)c(C(C)(C)C)ccc2c1","inchiKey":"WBEBQCINXJDZCX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIBUNIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dibunate"],"crossReferences":{"PubChem":["124893716","50125928"],"drugbank":["DB13796"]},"childChemblIds":["CHEMBL2107554"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1908372","canonicalSmiles":"CCN1CCN(C(=O)N[C@@H](C(=O)N[C@]2(OC)C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@@H]32)[C@H](C)O)C(=O)C1=O","inchiKey":"SMSRCGPDNDCXFR-CYWZMYCQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFBUPERAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMY-25182","Cefbuperazone","Cefbuperazone sodium","T-1982"],"crossReferences":{"drugbank":["DB13638"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL19224","canonicalSmiles":"COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC","inchiKey":"XQYZDYMELSJDRZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PAPAVERINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-136630","Papaverine","Papaverinum"],"crossReferences":{"PubChem":["11111623","11111624","11111625","124881091","50104295","90341237"],"TG-GATEs":["98"],"Wikipedia":["Papaverine"],"drugbank":["DB01113"],"chEBI":["28241"]},"childChemblIds":["CHEMBL98123"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for erectile dysfunction and gastrointestinal disease and has 4 investigational indications."}
{"id":"CHEMBL195836","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CCC4=C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O","inchiKey":"BTTWKVFKBPAFDK-LOVVWNRFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL195836","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"Wikipedia":["4-Androstenediol"],"drugbank":["DB01526"],"chEBI":["34386"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2074725","canonicalSmiles":"CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O","inchiKey":"HWKJSYYYURVNQU-DXJNJSHLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACETYLDIGOXIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-acetyldigoxin","Acetyldigoxin","Digoxin, 3'''-acetate","Lanatilin","Sandolanid","beta-Acetyldigoxin"],"crossReferences":{"drugbank":["DB13691"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2074932","canonicalSmiles":"O=CC[C@@H](O)[C@H](O)[C@H](O)CO","inchiKey":"VRYALKFFQXWPIH-PBXRRBTRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEOXYGLUCOSE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08831"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103761","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1","inchiKey":"VXMOONUMYLCFJD-DHLKQENFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BARNIDIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Barnidipine","Barnidipine hydrochloride","Mepirodipine","Vasexten"],"crossReferences":{"drugbank":["DB09227"]},"childChemblIds":["CHEMBL2356712"],"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000151067","ENSG00000102001"],"count":4},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2104154","canonicalSmiles":"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1cccc2nonc12","inchiKey":"QERUYFVNIOLCHV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DARODIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Darodipine","PY 108-068","PY-108-068"],"crossReferences":{"drugbank":["DB09234"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105949","canonicalSmiles":"COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1.Cl","inchiKey":"NHSNLUIMAQQXGR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARZOXIFENE HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL226267","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Arzoxifene hcl","Arzoxifene hydrochloride","LY-353381.HCL","LY353381.HCL","SERM 3","SERM-3"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2106083","canonicalSmiles":"C[N+](C)(C)CCOC(Cc1ccccc1)c1ccccc1.[Br-]","inchiKey":"APVMLVNTOWQOHL-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"BIBENZONIUM BROMIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2110796","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bibenzonium bromide","Sodobex"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106284","canonicalSmiles":"CCOC(=O)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1","inchiKey":"LQGIXNQCOXNCRP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIOXAPHETYL BUTYRATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acscn-9621","Amidalgon","Dioxaphetyl butyrate","IDS-ND-015","Spasmoxal","Spasmoxale"],"crossReferences":{"drugbank":["DB01475"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108667","drugType":"Antibody","blackBoxWarning":true,"name":"YTTRIUM Y 90 IBRITUMOMAB TIUXETAN","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["(90)y-ibritumomab tiuxetan","90y ibritumomab tiuxetan","90y-ibritumomab","BAY-86-5128","Ibritumomab tiuxetan","Ibritumomab tiuxetan y-90","Yttrium y 90 ibritumomab tiuxetan"],"linkedTargets":{"rows":["ENSG00000156738"],"count":1},"linkedDiseases":{"rows":["EFO_0009441","MONDO_0013730","MONDO_0000873","MONDO_0019465","MONDO_0044887","EFO_0000403","EFO_1001469","EFO_0005952","EFO_0000565","EFO_0000309","EFO_1001365","EFO_0003032","EFO_0000096","EFO_0000095","MONDO_0019088","EFO_1000630","EFO_0000191","EFO_0000574","EFO_0001378","EFO_0000183","MONDO_0018906","EFO_1000550"],"count":22},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 18 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108739","drugType":"Antibody","blackBoxWarning":false,"name":"PLACULUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ART-621","ART-621 ( ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY)","ART621","CEP-37247","PN-0621","PN0621","Placulumab"],"linkedTargets":{"rows":["ENSG00000232810"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","HP_0011868"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108981","drugType":"Unknown","blackBoxWarning":false,"name":"ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-thymocyte globulin equine","Antilymphocyte immunoglobulin (horse)","Atgam","Equine anti-thymocyte globulin","Equine thymocyte immune globulin","Horse anti-thymocyte globulin","Horse atg"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109150","drugType":"Antibody","blackBoxWarning":false,"name":"LINTUZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Zamyl"],"synonyms":["HUM-195","HUM195","Huma-195-Gelonin","Lintuzumab","SGN-33"],"linkedTargets":{"rows":["ENSG00000105383"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000565","EFO_1001779","MONDO_0001475","EFO_0000222","EFO_0001378"],"count":6},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109265","drugType":"Antibody","blackBoxWarning":false,"name":"MOC31-PE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MOC31-PE","Moc31-pe"],"linkedTargets":{"rows":["ENSG00000119888"],"count":1},"linkedDiseases":{"rows":["EFO_0000313"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109401","drugType":"Antibody","blackBoxWarning":false,"name":"AV-203","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AV-203","AV203","Av 203","Av-203","CAN-017"],"linkedTargets":{"rows":["ENSG00000065361"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109592","drugType":"Antibody","blackBoxWarning":false,"name":"MEDI-500","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEDI-500","Medi-500","T10B9"],"description":"Antibody drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2218898","canonicalSmiles":"CC[C@H](C)[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCSCC[C@@H](C(=O)N(C)[C@H](CO)CCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@H](C)CC)NC1=O","inchiKey":"UGNGRKKDUVKQDF-IHOMMZCZSA-N","drugType":"Protein","blackBoxWarning":false,"name":"BARUSIBAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Barusiban","Fe-200440"],"crossReferences":{"drugbank":["DB12292"]},"linkedTargets":{"rows":["ENSG00000180914"],"count":1},"linkedDiseases":{"rows":["EFO_0000545"],"count":1},"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL229264","canonicalSmiles":"Cc1c(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)ccc(C#N)c1Cl","inchiKey":"KEJORAMIZFOODM-PWSUYJOCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-564929","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-564929"],"crossReferences":{"drugbank":["DB07286"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL230011","canonicalSmiles":"Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1","inchiKey":"UJIAQDJKSXQLIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TG100-115","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TG100-115","Tg100-115"],"crossReferences":{"drugbank":["DB05552"]},"linkedTargets":{"rows":["ENSG00000171608","ENSG00000105851"],"count":2},"linkedDiseases":{"rows":["EFO_0000612"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL25336","canonicalSmiles":"C(=N/NC1=NCCN1)\\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12","inchiKey":"NJSMWLQOCQIOPE-OCHFTUDZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BISANTRENE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bisantrene","NSC-337766"],"childChemblIds":["CHEMBL3989424"],"linkedTargets":{"rows":["ENSG00000140718"],"count":1},"linkedDiseases":{"rows":["EFO_0000222"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL270362","canonicalSmiles":"CCCc1cc(=O)oc2c3c(c4c(c12)OC(C)(C)C=C4)OC(C)C(C)C3O","inchiKey":"NIDRYBLTWYFCFV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CALANOLIDE A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Calanolide a","NSC-650886"],"crossReferences":{"PubChem":["26665012"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL303992","canonicalSmiles":"N=C(N)c1ccc2[nH]c(-c3cccc(OC4CCCC4)c3O)nc2c1","inchiKey":"WCFWDBPDMBXMTQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL303992","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02526"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL308745","canonicalSmiles":"CCCCN/C(N)=N/O","inchiKey":"ULDDTFAPYWLDGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL308745","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02727"]},"childChemblIds":["CHEMBL2398455"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3137301","canonicalSmiles":"CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O","inchiKey":"PYNXFZCZUAOOQC-UTKZUKDTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SACUBITRIL","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["AHU-377","AHU377","Sacubitril"],"crossReferences":{"DailyMed":["sacubitril"],"drugbank":["DB09292"]},"linkedTargets":{"rows":["ENSG00000196549"],"count":1},"linkedDiseases":{"rows":["MONDO_0005149","EFO_0005529","EFO_0000373","EFO_0000538","EFO_0000537","EFO_0007148","MONDO_0001302","HP_0012664","EFO_0008585","MONDO_0100096","EFO_0003144","EFO_0008583","EFO_1001207","EFO_0000612","HP_0031273","EFO_0000400","EFO_0004265"],"count":17},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for congestive heart failure and heart failure and has 9 investigational indications."}
{"id":"CHEMBL316053","canonicalSmiles":"Nc1nccc2ccc(CN3CC[C@H](NS(=O)(=O)c4cc5ncccc5s4)C3=O)cc12","inchiKey":"NVKDOURNRJCKJE-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL316053","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07261"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3186864","canonicalSmiles":"CCCCCCC(O)CO","inchiKey":"AEIJTFQOBWATKX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3186864","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144211336"],"drugbank":["DB14589"],"chEBI":["34056"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL320775","canonicalSmiles":"Cc1ccc2nc(N)[nH]c(=O)c2c1Sc1ccncc1","inchiKey":"XHWRWCSCBDLOLM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NOLATREXED","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nolatrexed"],"crossReferences":{"PubChem":["50125758"],"drugbank":["DB12912"]},"childChemblIds":["CHEMBL1983788","CHEMBL2356692"],"linkedTargets":{"rows":["ENSG00000176890"],"count":1},"linkedDiseases":{"rows":["MONDO_0002691"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3275971","canonicalSmiles":"CC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C","inchiKey":"ILCTUFVQFCIIDS-NGFSFWIMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3275971","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB13951"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3287255","canonicalSmiles":"O=C(CCCCNC(=O)c1nc(-c2nccs2)sc1C1CC1)NO","inchiKey":"MVJAEZIEZVJAFM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BISTHIANOSTAT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bisthianostat"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL334966","canonicalSmiles":"CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"PAEBIVWUMLRPSK-IDTAVKCVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANGRELOR","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["AR-C69931XX","Cangrelor"],"crossReferences":{"DailyMed":["cangrelor"],"drugbank":["DB06441"]},"childChemblIds":["CHEMBL1097279"],"linkedTargets":{"rows":["ENSG00000169313"],"count":1},"linkedDiseases":{"rows":["EFO_0008585","EFO_0001645","EFO_0000556","EFO_0008583","EFO_0000612","HP_0004419","GO_0070527","HP_0031273","EFO_0005672"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for recurrent thrombophlebitis and myocardial infarction and has 4 investigational indications."}
{"id":"CHEMBL336360","canonicalSmiles":"CC(CCCCCCCCCCCCc1ccc(I)cc1)CC(=O)O","inchiKey":"NPCIWINHUDIWAV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IODOFILTIC ACID","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL3989901"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545062","canonicalSmiles":"COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1","inchiKey":"FHCUMDQMBHQXKK-CDIODLITSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VELPATASVIR","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GS-5816","Velpatasvir"],"crossReferences":{"DailyMed":["velpatasvir"],"drugbank":["DB11613"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for chronic hepatitis c virus infection and has 1 investigational indication."}
{"id":"CHEMBL3545092","drugType":"Small molecule","blackBoxWarning":false,"name":"CR 1447","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cr 1447"],"linkedTargets":{"rows":["ENSG00000140009","ENSG00000169083"],"count":2},"linkedDiseases":{"rows":["EFO_0000304"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545408","canonicalSmiles":"O=C1c2ccccc2C(=O)N1[C@@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)C1O5","inchiKey":"DHAITNWJDOSRBU-RCSSWNHXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NALTALIMIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Naltalimide","TAK-363","TAK363","Trk-130"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545420","canonicalSmiles":"CCNCc1cncc(-c2ccc3c(c2)/C(=C2/N=c4cc(F)cc(F)c4=N2)NN3)c1C","inchiKey":"RBOKLZGCVRXGEP-XTQSDGFTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AG-24322","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AG-024322","Ag 024322","Ag-24322"],"linkedTargets":{"rows":["ENSG00000123374","ENSG00000135446","ENSG00000170312"],"count":3},"linkedDiseases":{"rows":["EFO_0005952"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545426","drugType":"Small molecule","blackBoxWarning":false,"name":"CC-115","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cc-115"],"linkedTargets":{"rows":["ENSG00000253729","ENSG00000198793"],"count":2},"linkedDiseases":{"rows":["EFO_0000637","EFO_0000095","EFO_0000519","MONDO_0008315","EFO_0000181","EFO_0009708"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL35505","canonicalSmiles":"NNc1nnc(NN)c2ccccc12","inchiKey":"VQKLRVZQQYVIJW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIHYDRALAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihydralazine","NSC-526654"],"crossReferences":{"PubChem":["144205206","170466387","29215360"],"Wikipedia":["Dihydralazine"],"drugbank":["DB12945"]},"childChemblIds":["CHEMBL2106266"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3559670","drugType":"Small molecule","blackBoxWarning":false,"name":"LYAPOLATE SODIUM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Peson"],"synonyms":["Lyapolate","Lyapolate sodium","Sodium apolate","Sodium polyethylenesulfonate"],"crossReferences":{"DrugCentral":["4705"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL357217","canonicalSmiles":"COC1=CC(=O)c2c(c(COc3ccc([N+](=O)[O-])cc3)c(C)n2C)C1=O","inchiKey":"IBLWSLZYYZHSRG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ES-936","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ES-936"],"crossReferences":{"drugbank":["DB02400"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3659477","canonicalSmiles":"CCCOc1ccc([C@H]2CNC(=O)N2c2ccc3nc[nH]c3c2)cc1","inchiKey":"XHIKZWOEFZENIX-GOSISDBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VAROGLUTAMSTAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PQ-912","PQ912","Pq912","Varoglutamstat"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3681949","canonicalSmiles":"C#Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(C(C)(C)C)cc(NS(C)(=O)=O)c4OC)c4ccccc34)n2)cc(C(=O)NCCOCCOCCOC)c1","inchiKey":"FWXVGKSWZJEPQI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TOP-1288","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TOP-1288","TOP1288","Top-1288","Top1288"],"crossReferences":{"drugbank":["DB14839"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3707323","drugType":"Protein","blackBoxWarning":false,"name":"SOMAVARATAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Somavaratan","VRS-317"],"description":"Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL383189","canonicalSmiles":"CC(C)NCCCn1c(Sc2cc3c(cc2Br)OCO3)nc2c(N)ncnc21","inchiKey":"MWGWLDJLENCVRQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL383189","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07877"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989678","canonicalSmiles":"C1CNCCN1.C1CNCCN1.C1CNCCN1.O.O=C(O)CC(O)(CC(=O)O)C(=O)O.O=C(O)CC(O)(CC(=O)O)C(=O)O","inchiKey":"LWMBPKJYEQGDLN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPERAZINE CITRATE","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3990694","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antepar","Bryrel","Multifuge","Piperazine citrate","Vermidol"],"synonyms":["Piperazine citrate"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."}
{"id":"CHEMBL3989694","canonicalSmiles":"Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O","inchiKey":"ZIMCQJVMPKQQPB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"OLANZAPINE PAMOATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL715","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zyprexa relprevv"],"synonyms":["Olanzapine (as embonate)","Olanzapine embonate","Olanzapine pamoate","Olanzapine pamoate anhydrous","Olanzapine pamoate monohydrate","Zypadhera"],"crossReferences":{"DailyMed":["olanzapine%20pamoate"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000069696","ENSG00000102468","ENSG00000151577","ENSG00000147246"],"count":5},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0009963","HP_0000713"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3989920","canonicalSmiles":"O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]","inchiKey":"NBDQGOCGYHMDSJ-NRFPMOEYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"PITAVASTATIN SODIUM","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201753","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nikita"],"synonyms":["Pitavastatin sodium"],"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["HP_0003124","MONDO_0021187","HP_0003119","EFO_0004911"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved indications."}
{"id":"CHEMBL3989969","canonicalSmiles":"C[C@@H](O)C(=N)NS(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F","inchiKey":"CWNLBPBIFALUQD-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OPIGOLIX","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ASP-1707","ASP1707","Opigolix","Opigolixum"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0001065"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989984","drugType":"Antibody","blackBoxWarning":false,"name":"NAVICIXIZUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Navicixizumab","OMP-305B83","Omp 305b83"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3990034","drugType":"Gene","blackBoxWarning":false,"name":"FIDANACOGENE ELAPARVOVEC","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aav8 hfix19","Fidanacogene elaparvovec","PF-06838435","Raav-spark100-hfix-padua","SPK 101","SPK-1001","SPK-9001","SPK-FIX Padua","Spark 101"],"linkedTargets":{"rows":["ENSG00000101981"],"count":1},"linkedDiseases":{"rows":["Orphanet_98879"],"count":1},"description":"Gene drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3990248","drugType":"Small molecule","blackBoxWarning":false,"name":"GOLD SODIUM THIOSULFATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL3833379"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4071161","canonicalSmiles":"CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1","inchiKey":"SEJLPXCPMNSRAM-GOSISDBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIRABRUTINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-4059","Gs-4059","ONO-4059","ONO-4059(FREE BASE)","Ono-4059","Tirabrutinib"],"crossReferences":{"drugbank":["DB15227"]},"linkedTargets":{"rows":["ENSG00000010671"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0005531","EFO_0000095","MONDO_0044887","EFO_0000699","EFO_0000311"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL415606","canonicalSmiles":"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O","inchiKey":"MEUCPCLKGZSHTA-XYAYPHGZSA-N","drugType":"Protein","blackBoxWarning":false,"name":"DEGARELIX","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Firmagon"],"synonyms":["Degarelix","FE200486 (AS ACETATE SALT)"],"crossReferences":{"DailyMed":["degarelix%20acetate"],"drugbank":["DB06699"]},"childChemblIds":["CHEMBL2028987"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000545","MONDO_0100096","EFO_0001065","EFO_0000673","MONDO_0007254","EFO_0000196","EFO_0000284","MONDO_0021259","EFO_0000228","MONDO_0008315","EFO_0001663","HP_0011277"],"count":13},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 10 investigational indications."}
{"id":"CHEMBL417656","canonicalSmiles":"CC1(C)O[C@H]2[C@@H]3OS(=O)(=O)O[C@@H]3CO[C@@]2(COS(N)(=O)=O)O1","inchiKey":"GGOAQSGCBDRTHT-JAKMQLQISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL417656","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02894"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297258","canonicalSmiles":"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C","inchiKey":"GHKOONMJXNWOIW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALFLUTINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AST-2818","AST2818","Alflutinib","Furmonertinib"],"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["EFO_0000571","MONDO_0008903","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297318","canonicalSmiles":"COc1ccc(C(=O)Nc2ccc(S(=O)(=O)NC(CC#CCN3CCOCC3)C(=O)O)cc2)cc1","inchiKey":"JAYVKNDQKXUNOJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PG-530742","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PG-116800","PGE-7113313","PGE7113313","Pg-530742"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297361","canonicalSmiles":"C=C1/C(=C\\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CC[C@@H](CC)C(C)C)C[C@@H](O)C[C@@H]1O","inchiKey":"NWFOBODUYTUMNC-VPSCEVSQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1.ALPHA.-HYDROXYVITAMIN D5","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1.alpha.-hydroxyvitamin d5","CARD-024","Card-024","LS-144738","MN-201"],"crossReferences":{"drugbank":["DB13097"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297445","canonicalSmiles":"Cc1cc(Cc2c(C)nn(CCC(=O)O)c2C)c2c(c1O)CCC2","inchiKey":"OFUOCIUIWKDKPA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRC-150094","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Omzotirome","TRC-150094","TRC150094","Trc-150094","Trc150094"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297558","drugType":"Antibody","blackBoxWarning":false,"name":"INOTUZUMAB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Besponsa"],"synonyms":["G544","Inotuzumab"],"linkedTargets":{"rows":["ENSG00000012124"],"count":1},"linkedDiseases":{"rows":["EFO_0000220"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL4297647","canonicalSmiles":"CC(C)Oc1ccc(-c2nc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)c3oc4ccccc4c3n2)cc1","inchiKey":"GZRNOYTVBWWFLJ-NTPALUMKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURAPREVIR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Furaprevir","TG-2349","Tg-2349"],"crossReferences":{"drugbank":["DB12785"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297715","drugType":"Antibody","blackBoxWarning":false,"name":"CAMRELIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Camrelizumab","SHR-1210","Shr-1210"],"linkedTargets":{"rows":["ENSG00000188389"],"count":1},"linkedDiseases":{"rows":["MONDO_0003060","EFO_0000637","EFO_0000365","EFO_0011061","EFO_0000756","EFO_1000657","EFO_0005952","EFO_1001951","MONDO_0020669","EFO_0000178","MONDO_0002974","MONDO_0008903","EFO_0000182","MONDO_0016784","EFO_0001416","EFO_0002618","EFO_0005922","MONDO_0002108","MONDO_0008170","EFO_0000349","EFO_0005842","EFO_1001968","EFO_0005221","EFO_0000294","MONDO_0002691","EFO_0001061","MONDO_0000544","EFO_0003868","EFO_0005537","MONDO_0019472","EFO_0000574","EFO_1000796","MONDO_0021355","MONDO_0009348","EFO_0002938","MONDO_0021117","MONDO_0044887","MONDO_0007254","EFO_0001071","EFO_0004252","MONDO_0021063","EFO_0000708","MONDO_0001056","EFO_1001480","EFO_1000218","EFO_0000183","EFO_0000707","EFO_0000616","EFO_0009780","EFO_0002916","EFO_0000503","Orphanet_59305","EFO_0000403","MONDO_0007576","EFO_0000313","EFO_0000222","EFO_0003060","EFO_0000311","EFO_1001961","MONDO_0002120","EFO_0000702","EFO_0000199","EFO_0004142","EFO_0000691","EFO_0000519","EFO_0000181","MONDO_0001128"],"count":67},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 54 investigational indications."}
{"id":"CHEMBL4297874","drugType":"Unknown","blackBoxWarning":false,"name":"AFM-11","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AFM11","Afm-11","Afm11"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297885","drugType":"Protein","blackBoxWarning":false,"name":"SOLNATIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AP-301","AP301","Ap-301","Ap301","Solnatide"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297891","drugType":"Antibody","blackBoxWarning":false,"name":"CUSATUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Argx-110","Cusatuzumab"],"linkedTargets":{"rows":["ENSG00000125726"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0000222","EFO_0000311"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298188","drugType":"Antibody","blackBoxWarning":false,"name":"ODESIVIMAB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Odesivimab","Odesivimab-ebgn","REGN-3471","REGN3471"],"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for ebola hemorrhagic fever."}
{"id":"CHEMBL438","canonicalSmiles":"Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1","inchiKey":"QPPBRPIAZZHUNT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFAMERAZINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mesulfa","Methypyrimal","Sulfamethyldiazine","Sumedin"],"synonyms":["NSC-27259","Sulfamerazine","Sulfamerazine (trisulfapyrimidines)","Sulphamerazine"],"crossReferences":{"PubChem":["11112279","124882173","14742044","170464738","26748261","50086854"],"Wikipedia":["Sulfamerazine"],"drugbank":["DB01581"],"chEBI":["102130"]},"childChemblIds":["CHEMBL2107260"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for bacterial disease."}
{"id":"CHEMBL441","canonicalSmiles":"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O","inchiKey":"IUJDSEJGGMCXSG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THIOPENTAL","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Thiopental","Thiopental ciii"],"crossReferences":{"PubChem":["29215503"],"drugbank":["DB00599"],"chEBI":["102166"]},"childChemblIds":["CHEMBL738"],"linkedTargets":{"rows":["ENSG00000145864","ENSG00000166206","ENSG00000163288"],"count":3},"linkedDiseases":{"rows":["EFO_0008526","HP_0000486","EFO_0006834","EFO_1001454","EFO_0001645","MONDO_0043510"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 5 investigational indications."}
{"id":"CHEMBL4457723","canonicalSmiles":"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1","inchiKey":"PJTGSIKANITYOO-RCOXNQKVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-741672","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS 741672","Bms-741672","Bms741672"],"linkedTargets":{"rows":["ENSG00000121807"],"count":1},"linkedDiseases":{"rows":["EFO_0005762"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4514636","canonicalSmiles":"C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1","inchiKey":"MGZKYOAQVGSSGC-DLBZAZTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FISOGATINIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BLU-111362","BLU-554","BLU111362","Fisogatinib","X-439161","X439161"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL452","canonicalSmiles":"O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1","inchiKey":"DGBIGWXXNGSACT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CLONAZEPAM","yearOfFirstApproval":1975,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clonazepam","Klonopin","Klonopin rapidly disintegrating","Rivotril"],"synonyms":["Clonazepam","Clonazepam civ","NSC-179913","RO 5-4023","RO-5-4023","RO-54023","Ravotril","Rivatril"],"crossReferences":{"DailyMed":["clonazepam"],"Wikipedia":["Clonazepam"],"drugbank":["DB01068"],"chEBI":["3756"]},"linkedTargets":{"rows":["ENSG00000022355","ENSG00000182256","ENSG00000011677","ENSG00000113327","ENSG00000151834","ENSG00000163285","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["EFO_0005762","EFO_0008526","MONDO_0005090","EFO_0004262","EFO_1000924","HP_0000726","EFO_0001358","EFO_1001917","HP_0001250","EFO_0003843","EFO_0007191","EFO_0000474","MONDO_0002050","EFO_1000632","EFO_0007262","EFO_0005230","EFO_1000850","EFO_0007462","EFO_0009492"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4594271","canonicalSmiles":"N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1","inchiKey":"UXNXMBYCBRBRFD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BEROTRALSTAT","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BCX-7353","BCX7353","Bcx7353","Berotralstat"],"childChemblIds":["CHEMBL4594272"],"linkedTargets":{"rows":["ENSG00000164344"],"count":1},"linkedDiseases":{"rows":["Orphanet_91378"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication."}
{"id":"CHEMBL4594583","drugType":"Unknown","blackBoxWarning":false,"name":"RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OTO-413","OTO-413 (BDNF)","Oto-413","R-met-hu-bdnf","Recombinant methionyl human bdnf","Recombinant methionyl human brain-derived neurotrophic factor"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4594602","drugType":"Unknown","blackBoxWarning":false,"name":"RO-7121661","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RO-7121661","RO7121661","Ro-7121661","Ro7121661"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4650388","drugType":"Unknown","blackBoxWarning":false,"name":"CVX-241","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CVX-241","CVX241","Cvx-241","PF-05057459","PF05057459"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650433","drugType":"Unknown","blackBoxWarning":false,"name":"ABC-008","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABC-008","ABC008","Abc-008","Abc008"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4802148","canonicalSmiles":"C=C1C[C@@H]2CC[C@@]34C[C@@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)O[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H]1C[C@H]2O[C@@]4(C[C@@H]5O[C@]6(C[C@H](C)[C@@H]7O[C@H](CN)[C@H](O)C[C@@H]7O6)C[C@H](C)[C@@H]5O4)C[C@H]2O[C@H]1[C@@H]3C","inchiKey":"MJMBDBINYFNDST-UWJPGFHWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"E-7130","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["C52-halichondrin-b amine","E-7130","E7130"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4802169","drugType":"Protein","blackBoxWarning":false,"name":"CAGRILINTIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cagrilintide"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL489514","canonicalSmiles":"Cc1csc(NC(=O)c2cc(Sc3nncn3C)ccc2N)n1","inchiKey":"JEBOJMQHVUEKBE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL489514","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07358"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL517199","canonicalSmiles":"Cc1cccc(C)c1NC(=O)c1cc(S(N)(=O)=O)c(Cl)cc1O","inchiKey":"MTZBBNMLMNBNJL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XIPAMIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Diurexan"],"synonyms":["BE-1293","MJF 10,938","MJF-10938","Xipamide"],"crossReferences":{"PubChem":["144206528","170466623"],"Wikipedia":["Xipamide"],"drugbank":["DB13803"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."}
{"id":"CHEMBL631","canonicalSmiles":"CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1","inchiKey":"JWHAUXFOSRPERK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROPAFENONE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GNF-Pf-4594","Propafenon hexal","Propafenone","Rythmol"],"crossReferences":{"DailyMed":["propafenone%20hydrochloride"],"PubChem":["104171212","124881115","144203779","170464755","26752315","26752316","50105251","50105252","90341088"],"Wikipedia":["Propafenone"],"drugbank":["DB01182"],"chEBI":["63619"]},"childChemblIds":["CHEMBL1201063"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000196876","ENSG00000007314","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169252","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000043591","ENSG00000153253"],"count":12},"linkedDiseases":{"rows":["EFO_0000275","EFO_0004269","EFO_0004287","EFO_0003144","EFO_0005306","HP_0004308","EFO_0004278","EFO_0000612"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL672","canonicalSmiles":"CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1","inchiKey":"YMTINGFKWWXKFG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENOFIBRATE","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antara","Antara (micronized)","Fenofibrate","Fenofibrate (micronized)","Fenogal","Fenoglide","Lipantil","Lipantil micro 200","Lipantil micro 267","Lipantil micro 67","Lipidil","Lipofen","Supralip 160","Tricor","Tricor (micronized)","Triglide"],"synonyms":["Fenofibrate","Fenofibrate delayed release","Fenofibrate micronized","NSC-281319"],"crossReferences":{"DailyMed":["fenofibrate"],"PubChem":["104171156","11111181","11111182","124880099","144203698","144210471","170464718","174007303","26746914","26751450","50103926","56422492","85231046","855565","90340778"],"TG-GATEs":["79"],"Wikipedia":["Fenofibrate"],"drugbank":["DB01039"],"chEBI":["5001"]},"linkedTargets":{"rows":["ENSG00000186951"],"count":1},"linkedDiseases":{"rows":["EFO_0000401","EFO_1001249","MONDO_0037748","EFO_1001486","EFO_1000727","EFO_0004211","EFO_0003914","HP_0003119","MONDO_0007079","EFO_0000400","EFO_0004705","HP_0003124","EFO_0001645","EFO_0000180","EFO_0003770","EFO_0009516","EFO_1002009","EFO_0000319","EFO_0001073","Orphanet_309005","EFO_0000537","EFO_0000195","EFO_0000589","Orphanet_399","EFO_0004268","MONDO_0100096","MONDO_0021187","Orphanet_412","Orphanet_79211","EFO_0001378","MONDO_0005148","HP_0012594"],"count":32},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 23 investigational indications."}
{"id":"CHEMBL7087","canonicalSmiles":"NCCc1ccc(S(N)(=O)=O)cc1","inchiKey":"FXNSVEQMUYPYJS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-(2-Aminoethyl)Benzenesulfonamide","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-(2-Aminoethyl)Benzenesulfonamide"],"crossReferences":{"PubChem":["24841210"],"drugbank":["DB08782"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL75124","canonicalSmiles":"CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1","inchiKey":"RGOVYLWUIBMPGK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NONIVAMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AH-23491X","FEMA NO. 2787","Hansaplast","Hydroxymethoxybenzyl pelargonamide","N-vanillylnonamide","NSC-172795","Nonivamide","Nonylic acid vanillyamide","Pseudocapsaicin"],"crossReferences":{"PubChem":["11111961","144203853","144211535","170466476","26747691","26753670","50107151","56463512","85231285"],"drugbank":["DB11324"],"chEBI":["46936"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL797","canonicalSmiles":"CN1C(=O)CC(c2ccccc2)C1=O","inchiKey":"WLWFNJKHKGIJNW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENSUXIMIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Milontin"],"synonyms":["1-methyl-3-phenylsuccinimide","Epimid","Lifene","Milonton","Mirontin","NSC-760079","PM-334","Phensuximid","Phensuximide","Racemic phensuximide","Succitimal"],"crossReferences":{"PubChem":["144203933","170465315","56463169"],"Wikipedia":["Phensuximide"],"drugbank":["DB00832"],"chEBI":["8079"]},"linkedTargets":{"rows":["ENSG00000100346","ENSG00000006283","ENSG00000196557"],"count":3},"linkedDiseases":{"rows":["EFO_0000474"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy."}
{"id":"CHEMBL83063","canonicalSmiles":"CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1","inchiKey":"IOVGROKTTNBUGK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RITODRINE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["DU-21220","Ritodrine"],"crossReferences":{"PubChem":["174007152"]},"childChemblIds":["CHEMBL1367605"],"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["EFO_0003917"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."}
{"id":"CHEMBL8739","canonicalSmiles":"CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O","inchiKey":"DTOSIQBPPRVQHS-PDBXOOCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LINOLENIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144204622","144208925","144213639","17388945","26752892","29215108","50105513","57260459"],"Wikipedia":["Alpha-Linolenic_acid"],"drugbank":["DB00132"],"chEBI":["27432"]},"childChemblIds":["CHEMBL3122087"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL93124","canonicalSmiles":"CNc1ccc(-c2nc3ccc(O)cc3s2)cc1","inchiKey":"ZQAQXZBSGZUUNL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PITTSBURGH COMPOUND B","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL207456","CHEMBL1672899","CHEMBL1788111"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL962","canonicalSmiles":"CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\\CCCC(=O)[O-])C[C@@H]21.[Na+]","inchiKey":"LMHIPJMTZHDKEW-XQYLJSSYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"EPOPROSTENOL SODIUM","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1139","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Epoprostenol sodium","Flolan","Veletri"],"synonyms":["Epoprostenol sodium","Epoprostenolsodium","Prostacyclin sodium salt","Sodium prostacyclin","U-53,217A","U-53217A"],"crossReferences":{"DailyMed":["epoprostenol%20sodium"],"PubChem":["144205984"],"Wikipedia":["Prostacyclin"]},"linkedTargets":{"rows":["ENSG00000160013"],"count":1},"linkedDiseases":{"rows":["EFO_0001361","EFO_0000319"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for pulmonary arterial hypertension."}
